[MicroRNA-221 promotes colon carcinoma cell proliferation in vitro by inhibiting CDKN1C/p57 expression]

Kai Sun1, Wei Wang, Shang-tong Lei

  • 1Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. sunkai9602@sina.com

Abstract

Insights

MicroRNA-221 (MIR221) inhibits CDKN1C/p57 expression, promoting colon cancer cell growth. Targeting MIR221 may offer a new therapeutic strategy for colon carcinoma.

Area of Science:

  • Molecular Biology
  • Genetics
  • Oncology

Context:

  • Colon carcinoma is a significant global health concern.
  • MicroRNAs play crucial roles in cancer development and progression.
  • Understanding gene regulation in cancer cells is vital for therapeutic development.

Purpose:

  • To investigate the regulatory role of microRNA-221 (MIR221) on CDKN1C/p57 expression in colon carcinoma cells.
  • To elucidate the mechanism by which MIR221 affects colon cancer cell proliferation.
  • To assess the potential of MIR221 as a therapeutic target in colon cancer.

Summary:

  • MIR221 was found to directly interact with the 3'-UTR of CDKN1C/p57 mRNA, leading to its post-transcriptional silencing.
  • Inhibition of MIR221 significantly increased CDKN1C/p57 expression and suppressed colon cancer cell proliferation.
  • Luciferase reporter assays confirmed the direct interaction between MIR221 and CDKN1C/p57.
  • The study demonstrates that MIR221 promotes colon carcinoma cell proliferation by downregulating CDKN1C/p57.

Impact:

  • This research identifies MIR221 as a key regulator of CDKN1C/p57 in colon cancer.
  • The findings suggest that MIR221 is a potential therapeutic target for colon carcinoma treatment.
  • This study contributes to the understanding of microRNA-mediated gene regulation in cancer.

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...